Fatten Molecules Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 Cr
- Revenue Growth 10424.27%
- Profit Growth 37947.60%
- Ebitda 9875.32%
- Net Worth 12749.05%
- Total Assets 12076.09%
About Fatten Molecules
Fatten Molecules Private Limited (FMPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 December 2017 (Seven years and one month 25 days old ). Its registered office is in Jyotiba Phule Nagar, Uttar Pradesh, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹5.00 Cr.
Anup Singh, Sulabh Agarwal, Kirat Singh, and Two other members serve as directors at the Company.
Company Details
-
Location
Jyotiba Phule Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2017PTC099506
-
Company No.
099506
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Dec 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Fatten Molecules?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anup Singh
|
Director | 19-Dec-2017 | Current |
|
Sulabh Agarwal
|
Additional Director | 25-Sep-2021 | Current |
|
Kirat Singh
|
Director | 19-Dec-2017 | Current |
|
Pramod Kumar
|
Director | 19-Dec-2017 | Current |
|
Harjeet Ludher
|
Additional Director | 10-Dec-2021 | Current |
Financial Performance of Fatten Molecules.
Fatten Molecules Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10424.27% increase. The company also saw a substantial improvement in profitability, with a 37947.6% increase in profit. The company's net worth Soared by an impressive increase of 12749.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fatten Molecules?
Unlock access to Fatten Molecules's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Neosafe Bioscience Private LimitedKirat Singh is a mutual person
-
Shri-Da Chemicals Private Limited
Harjeet Ludher is a mutual person
Charges (Loans)
₹5.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 3.50 Cr
- State Bank Of India : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Aug 2024 | Hdfc Bank Limited | ₹3.50 Cr | Open |
| 09 Aug 2019 | State Bank Of India | ₹1.50 Cr | Open |
How Many Employees Work at Fatten Molecules?
Fatten Molecules has a workforce of 25 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fatten Molecules, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fatten Molecules's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
